Management of Tardive Dyskinesia and Drug-Induced Movement Disorders

Tardive dyskinesia (TD) and related drug-induced movement disorders represent a spectrum of involuntary hyperkinetic and hypokinetic syndromes arising predominantly from long-term exposure to dopamine receptor-blocking agents. These disorders encompass oro-buccal-lingual movements, akathisia, parkinsonism, dystonia and tremor, each contributing to functional impairment, social stigma and reduced quality of life. Management begins with risk mitigation through judicious antipsychotic prescribing, favouring agents with lower extrapyramidal risk and using the minimal effective dose. Early detection via routine clinical assessment enables prompt intervention. Symptomatic therapies centre on vesicular monoamine transporter 2 (VMAT2) inhibitors, which have demonstrated sustained reduction in dyskinetic movements. Adjunctive approaches, including botulinum toxin for focal dystonia and physical therapies, may further improve function. Multidisciplinary care, involving psychiatry, neurology, pharmacy and allied health professionals, is essential to tailor treatment, monitor safety and support adherence. Emerging evidence underscores the importance of patient-centred outcome measures and long-term surveillance to optimise both efficacy and tolerability across diverse populations.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Management of Tardive Dyskinesia and Drug-Induced Movement Disorders publication trend

The graph below shows the total number of articles in management of tardive dyskinesia and drug-induced movement disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Tardive Dyskinesia: A late-onset, involuntary movement disorder characterised by repetitive, purposeless movements, often of the face and tongue, induced by long-term dopamine receptor blockade.

Extrapyramidal side effects (EPSEs): A group of movement disorders—including parkinsonism, akathisia, dystonia and tardive syndromes—arising as adverse effects of antipsychotic medications.

Vesicular monoamine transporter 2 (VMAT2): A presynaptic protein responsible for packaging monoamines into synaptic vesicles; inhibition reduces synaptic dopamine release and ameliorates hyperkinetic movements.

Akathisia: A drug-induced condition marked by an inner sense of restlessness and an irresistible urge to move.

Parkinsonism: A syndrome characterised by tremor, rigidity and bradykinesia, resembling Parkinson’s disease but often reversible upon modification of causative medications.

Dystonia: Sustained or intermittent muscle contractions causing abnormal postures or repetitive movements, which may be focal or generalised and drug-induced.

References

1. An Update on Tardive Dyskinesia: From Phenomenology to Treatment. Tremor and Other Hyperkinetic Movements (2013).
2. NBI‐98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled study. Movement Disorders (2015).
3. Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. CNS Spectrums (2020).
4. Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies. PLOS ONE (2021).
5. Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. Quality of Life Research (2019).